Sanofi - 22 Year Stock Price History | SNY

Historical daily share price chart and data for Sanofi since 2002 adjusted for splits and dividends. The latest closing stock price for Sanofi as of April 24, 2024 is 46.61.
  • The all-time high Sanofi stock closing price was 55.20 on September 20, 2023.
  • The Sanofi 52-week high stock price is 55.93, which is 20% above the current share price.
  • The Sanofi 52-week low stock price is 42.63, which is 8.5% below the current share price.
  • The average Sanofi stock price for the last 52 weeks is 50.59.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Sanofi Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2024 48.3949 50.0000 52.4800 45.3900 46.6100 -6.27%
2023 50.4151 47.2188 55.2000 43.1300 49.7300 6.56%
2022 45.9468 47.2741 54.2438 35.8670 46.6695 -0.12%
2021 46.2298 43.8046 50.5942 40.8484 46.7239 7.02%
2020 43.8375 43.9442 48.3154 32.9668 43.6608 0.31%
2019 37.5120 35.6695 44.1002 33.9800 43.5280 20.49%
2018 34.3613 34.4147 37.9415 30.7126 36.1272 5.76%
2017 36.2936 31.5178 40.2061 30.3576 34.1605 9.94%
2016 30.4390 31.1005 32.7549 28.2778 31.0722 -1.15%
2015 35.6249 32.4899 40.5191 30.5920 31.4321 -3.45%
2014 36.3150 35.6542 40.8907 31.6905 32.5541 -11.90%
2013 34.8214 31.8955 38.1828 30.1517 36.9495 17.17%
2012 26.0578 23.6791 31.7025 22.2576 31.5361 35.70%
2011 22.4336 20.1758 25.6953 19.5918 23.2402 17.30%
2010 20.3638 24.2056 24.6384 17.3726 19.8131 -14.92%
2009 19.1149 18.3732 23.9446 14.0624 23.2864 28.83%
2008 19.4864 24.5691 26.2594 14.2647 18.0754 -26.25%
2007 23.3347 24.2362 25.9687 20.7793 24.5098 1.06%
2006 23.6523 23.4884 26.2637 21.6353 24.2519 7.32%
2005 21.3359 20.1284 23.2774 18.5910 22.5979 11.57%
2004 17.3024 18.6222 20.4571 14.3654 20.2549 9.66%
2003 14.4994 14.9987 18.4706 11.0171 18.4706 25.74%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $120.637B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Innoviva (INVA) United States $0.959B 6.77